The Eurazeo China Acceleration Fund (ECAF) – a France-China fund jointly launched by Eurazeo, China Investment Corporation (CIC) and BNP Paribas – has made its first bet by pouring 80 million euros ($95 million) into vitreoretinal surgery specialist Dutch Ophthalmic Research Centre (DORC).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
